(Q35630416)

9 August 2017

1 reference

title

Malaria vaccine developments (English)

1 reference

9 August 2017

0 references

1 reference

1 reference

3

Adrian V S Hill

1 reference

9 August 2017

2

Michael F Good

1 reference

9 August 2017

Vasee S Moorthy

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

363

1 reference

9 August 2017

issue

9403

1 reference

9 August 2017

page(s)

150-156

1 reference

Changing patterns of clinical malaria since 1965 among a tea estate population located in the Kenyan highlands

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

1 reference

7 January 2021

An overview of insecticide resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Malaria on the move: human population movement and malaria transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

The past, present and future of childhood malaria mortality in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A new global effort to control malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Immunology of vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Genome sequence of the human malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Immunization of man against sporozite-induced falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Development of a malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

1 reference

7 January 2021

An estimation of the number of malaria sporozoites ejected by a feeding mosquito

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Feeding behaviour and sporozoite ejection by infected Anopheles stephensi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Migration of Plasmodium sporozoites through cells before infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Migration through host cells activates Plasmodium sporozoites for infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Rapid effector function in CD8+ memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A proteomic view of the Plasmodium falciparum life cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915267-1

7 January 2021

10.1016/S0140-6736(03)15267-1

Identifiers

DOI

1 reference

9 August 2017

1 reference